XTL Biopharmaceuticals announced that Mr. Alex Rabinovich has been appointed as a member of the Company’s board of directors.
Mr. Rabinovich is a leading investor in XTL and holds over 20% of its shares. Mr. Rabinovich will replace Mr. David Bassa, who has resigned from his position as a director of the Company, after serving as a director for seven years.
Mr. Josh Levine, XTL’s CEO said that: “We are very happy to have Mr. Rabinovich join our Board of Directors and are certain that he can contribute from his vast experience in the capital markets. We would also like to take this opportunity to thank Mr. Bassa for his much appreciated contribution to XTL as a director throughout the years”.
XTL has recently reported raising $5.3 million: $2.5 million through a public offering and $2.8 million in a private placement from its existing shareholders, including Mr. Rabinovich and Mr. Bassa.